Efficacy and safety of pimecrolimus cream 1% in mild-to-moderate chronic hand dermatitis: A randomized, double-blind trial

Dermatology

Volumn 221, Issue 1, 2010, Pages 71-77

  Hordinsky, Maria ^a,g   Fleischer, Alan ^b   Rivers, Jason K ^e   Poulin, Yves ^f   Belsito, Donald ^c   Hultsch, Thomas ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Centre de Recherche Dermatologique du Quebec Metropolitain   (Canada)

^g UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Chronic hand dermatitis; Pimecrolimus cream 1 , efficacy, safety

Indexed keywords

PIMECROLIMUS;

ADULT; AGED; ARTICLE; BURN; CHRONIC HAND DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLOW UP; HEADACHE; HERPES SIMPLEX; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SKIN IRRITATION; STINGING; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 77955678545     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000297524     Document Type: Article

References (25)

1. Smit HA, Burdorf A, Coenraads PJ: Prevalence of hand dermatitis in different occupations. Int J Epidemiol 1993; 22: 288-293.
2. Friedmann PS: Allergy and the skin. II. Contact and atopic eczema. BMJ 1998; 316: 1226-1229.
3. Rietschel RL: Human and economic impact of allergic contact dermatitis and the role of patch testing. J Am Acad Dermatol 1995; 33: 812-815.
4. Warshaw EM: Therapeutic options for chronic hand dermatitis. Dermatol Ther 2004; 17: 240-250.
5. Veien NK, Olholm Larsen P, Thestrup-Pedersen K, Schou G: Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol 1999; 40: 882-886.
6. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ: Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1-15.
7. Fowler JF Jr: Efficacy of a skin-protective foam in the treatment of chronic hand dermatitis. Am J Contact Dermat 2000; 11: 165-169.
8. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthioff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264-273.
9. Stuetz A, Grassberger M, Meingassner JG: Pimecrolimus (Elidel, SDZ ASM 981)-preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20: 233-241.
10. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504.
11. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110:e2.
12. Ho VC, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, Fölster-Holst R, Potter P, Marshall K, Thurston M, Bush C, Cherill R: Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155-162.
13. Meurer M, Fölster-Holst, Wozel G, Weidinger G, Jünger M, Bräutigam M: Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271-277.
14. Luger T, Lahfa M, Fölster-Holst R, Gulliver WP, Allen R, Molloy S, Barbier N, Paul C, Bos JD: Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatol Treat 2004; 15: 169-178.
15. Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Bräutigam M: Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365-372.
16. Wolff K, Stuetz A: Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004; 5: 643-655.
17. Grassberger M, Steinhoff M, Schneider D, Luger TA: Pimecrolimus-an anti-inflammatory drug targeting the skin. Exp Dermatol 2004; 13: 721-730.
18. Thaçi D, Steinmeyer K, Ebelin ME, Scott G, Kaufmann R: Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective: an open study. Dermatology 2003; 207: 37-42.
19. Belsito DV, Fowler JF, Marks JG, Pariser DM, Hanifin J, Duarte IA, Pires MC, Cruz PD, Langley RG, Patel P, Bush C, Thurston M, Graeber M, Cherill R: Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004; 73: 31-38.
20. Vergnanini AL, Aoki V, Madi J: Comparative effects of pimecrolimus cream vehicle and three commercially available moisturizers on skin hydration and transepidermal water loss. J Am Acad Dermatol 2007; 56(suppl 2): AB60.
21. Burkhart CG, Burkhart HR: Contact irritant dermatitis and anti-pruritic agents: the need to address the itch. J Drugs Dermatol 2003; 2: 143-146.
22. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD: Low systemic exposure after repeated topical application of Pimecrolimus (Elidel , SD Z ASM 981) in patients with atopic dermatitis. Dermatology 2002; 204: 63-68.
23. Allen BR, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott G, Cardno M, Ebelin ME, Burtin P, Stephenson TJ: Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003; 88: 969-973.
24. Harper J, Lakhanpaul M, Wahn U, Pariser D, Gottlieb AB, Kauffmann R, Eichenfield L, Langley R, Scott G, Ebelin ME, Burtin P: Pimecrolimus (Elidel , SDZ ASM 981) cream 1% levels are consistently low in children with extensive atopic dermatitis. J Eur Acad Dermatol Venereol 2001; 15(suppl 2): 109-110.
25. Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez-Vidaurre C, Seeger JD: Topical treatments with pimecrolimus, tacrolimus and medium-to high-potency corticosteroids, and risk of lymphoma. Dermatology 2009; 219: 7-21.